Tag

Eli Lilly

28 stories

Lilly Paid $1.26B to License Hanmi's GLP-2

Lilly's $75M upfront bet on Hanmi's once-monthly GLP-2 could reach $1.26B if sonefpeglutide survives FDA, and its main rival already stumbled.

Deals 4 days ago

Lilly Paid $3.2B for Kelonia's 100% CAR-T Response

Lilly's $3.2B upfront bet on Kelonia just got its first real validation: 18 of 18 myeloma patients hit MRD-negative status at one month.

Legal May 24, 2026

Moolenaar Targets $15.2B BMS Deal in China Crackdown

If Treasury acts on Moolenaar's COINS Act request, deals like BMS's $15.2B Hengrui partnership would need federal clearance before closing.

FDA May 18, 2026

FDA Cleared Lilly Foundayo in $9.3B Obesity Race

Lilly cleared Foundayo on April 1, but the label carries a required post-market trial for four serious risks, including MACE and liver injury.

Deals May 8, 2026

Lilly Drops $4.5B, Opens First Genetic Medicine Plant

Lilly's $4.5B Indiana bet includes the company's first genetic medicine plant and what could become the largest API site in U.S. history.

Deals May 6, 2026

Lilly Puts $4.5B More Into Indiana Complex

Lilly's $4.5B Lebanon push brings its U.S. decade commitment over $50B, with a tirzepatide API plant poised to be the country's largest.

FDA May 4, 2026

Celcuity Beats Piqray in Phase 3, Shares Jump 15%

Pfizer sold gedatolisib to Celcuity for $10 million upfront in 2021.

Deals Apr 20, 2026

Lilly Bets on Kelonia's In Vivo CAR-T

Lilly paid an undisclosed sum upfront for Kelonia Therapeutics on Monday, placing a large bet on in vivo CAR-T as its next platform priority.

Deals Apr 18, 2026

UCB Paid $1.15B for Neurona's Single-Dose Epilepsy Cell Therapy

UCB paid up to $650m upfront, with up to $500m in future milestones, to buy Neurona Therapeutics in a deal valued at up to $1.15bn.

Legal Apr 17, 2026

Revived: $176.5M Patent Verdict Leaves Lilly to Evaluate Options

The Court of Appeals for the Federal Circuit on Thursday reinstated the $176.5 million verdict that Teva won in 2022, reviving its claim that Eli Lilly's…

Deals Apr 17, 2026

Kailera Prices $625M IPO, Largest Biotech Since Moderna

Kailera Therapeutics priced its IPO at $625m, or $16 a share, on April 16 — at the top of its S-1 range and one of the largest biotech public offerings…

Deals Apr 17, 2026

Priced at $16, Kailera Raises $625M in Largest Biotech IPO Since 2018

Kailera Therapeutics priced its IPO at $16 a share Friday, raising $625 million, the largest biotech public offering in recent memory, topping Moderna's…

Deals Apr 16, 2026

Cleared $22B: Q1 2026 Obesity Deals Top 2025's Full-Year Total

Biopharma committed $22 billion to obesity and diabetes licensing deals in Q1 2026, clearing last year's full-year total of $20.3 billion with three…

FDA Apr 15, 2026

FDA Cleared Foundayo With 3 Postmarketing Safety Study Requirements

FDA cleared Foundayo, Eli Lilly's oral GLP-1 pill for obesity, on April 1, but the approval letter lists three postmarketing requirements tied to what the…

FDA Apr 13, 2026

Beats Venetoclax: Lilly's Jaypirca Posts 4th Phase 3 Win in CLL

Jaypirca chalked up its fourth positive phase 3 readout in chronic lymphocytic leukemia on Monday, and this one rewrites the treatment calculus: it's the…

Deals Apr 13, 2026

AbbVie Bought Two NaV1.8 Pain Assets from Haisco for $745M

AbbVie bought ex-China rights to two NaV1.8 sodium channel pain inhibitors from Beijing-based Haisco Pharmaceutical for up to $745 million.

Deals Apr 13, 2026

Kailera Files $528.5M Nasdaq IPO to Fund Four GLP-1 Obesity Drugs

Kailera filed for a $528.5 million Nasdaq IPO, pricing 33.33 million shares at $14 to $16 each.

Deals Apr 13, 2026

Regeneron Paid $40M to Enter Radiopharma; Telix Scores Up to $4.3B

Regeneron put $40 million on the table Sunday to partner with Telix Pharmaceuticals, the Australian biotech with one of the more active radiopharmaceutical…

FDA Apr 13, 2026

FDA Cleared Foundayo; Lilly Pre-Stocked $1.5B Before Approval

FDA cleared Foundayo eight days ago, and Eli Lilly was ready: the company pre-stocked $1.5 billion worth of the pill back in February, months before…

FDA Apr 8, 2026

Lilly Foundayo Clears FDA; Novo's Oral Holds 5-Point Lead

Lilly's oral obesity pill approved but trails Novo on weight loss. Pharma's M&A sprint added $7.9B in deals and Trump's tariffs landed with carveouts.

Deals Apr 7, 2026

Lilly Bets on Orexins, Tirzepatide Playbook Repeats

Eli Lilly acquires into the orexin drug class, betting the maturing CNS mechanism follows the same multi-indication arc as GLP-1.

FDA Apr 7, 2026

Novo Nordisk's 7.2 mg Wegovy Hits US Shelves at Triple the Standard Dose

Novo Nordisk's 7.2 mg Wegovy is now available in the US, tripling the standard 2.4 mg dose in a direct bid to reclaim ground lost to Lilly's Zepbound.

Deals Apr 6, 2026

Lilly Pays $7.8B for Centessa to Buy Into the Orexin Race

Lilly is paying $7.8B for Centessa — $38/share plus a $9 CVR — to grab cleminorexton, a Phase IIa orexin agonist for narcolepsy.

deals

Deals Apr 6, 2026

Anthropic Pays $400M for a 10-Person Ghost Company

Anthropic is paying ~$400M for Coefficient Bio, a sub-10-person stealth startup. The price signals how expensive life sciences AI talent has become.

FDA Apr 5, 2026

Novo Fires Back at Lilly's Foundayo With Competing Efficacy Data

Novo Nordisk published rival efficacy data the day after FDA approved Lilly's oral obesity pill Foundayo — but no head-to-head trial exists to back the claims.

Deals Apr 5, 2026

Lilly Pays $115M Upfront in Insilico AI Deal Worth Up to $2.75B

Eli Lilly paid $115M upfront for an AI collaboration with Insilico Medicine worth up to $2.75B, with milestone math that heavily favors Lilly.

FDA Apr 5, 2026

FDA Clears 7.2mg Wegovy HD for Novo Nordisk in 54-Day Sprint

FDA cleared Novo Nordisk's 7.2mg Wegovy HD in 54 days under its national priority program, pushing the GLP-1's efficacy ceiling higher.

fda

FDA Apr 5, 2026

Lilly's Oral GLP-1 Pill Cleared in 50 Days, Fastest NME Since 2002

Eli Lilly's oral GLP-1 pill orforglipron approved in 50 days under the FDA's CNPV pilot — the fastest new molecular entity approval since 2002.